Duration of Ceftriaxone in Enteric Fever

Evidence-Based Treatment Duration

• The UK guideline recommends ceftriaxone administration for 14 days to minimize relapse risk in patients with enteric fever, based on clinical evidence 1, 2
• To reduce the risk of relapse, treatment with ceftriaxone should be continued for 14 days, as stated by the UK's guideline evidence, applicable to enteric fever caused by Salmonella typhi and Salmonella paratyphi 1, 2

Practical Treatment Algorithm

• The American College of Physicians and other guideline societies imply that initial empirical therapy with ceftriaxone should be started immediately for suspected enteric fever in patients from Asia, where more than 70% of isolates are fluoroquinolone-resistant 1, 2
• Ceftriaxone treatment should be continued for a minimum of 14 days total to reduce relapse risk to less than 8% 1, 2

Critical Considerations

• Relapse rates with ceftriaxone are reported as less than 8% when 14-day courses are used, according to the UK guideline 1, 2
• Relapsed enteric fever carries an increased risk of complications, including intestinal perforation, encephalopathy, and death, highlighting the importance of completing the full 14-day course of ceftriaxone 1

Alternative Considerations

• If azithromycin is used instead of ceftriaxone, relapse rates are less than 3%, but this should still be continued for 14 days, as per the UK guideline 1
• Fluoroquinolones, when susceptible, have relapse rates less than 4% and average fever clearance time less than 4 days, but resistance is now more than 70% in isolates from Asia, according to the UK guideline 1, 2